CT120 for relapsed lymphoma after prior treatments
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests CT120 in people with B-cell non-Hodgkin’s lymphoma that has come back (relapsed) or did not respond well (refractory) to previous treatment. The goal is to find a safe dose and see whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70.
- Your lymphoma is a B-cell type, such as DLBCL, FL3b, follicular lymphoma that turned into DLBCL, or primary mediastinal large B-cell lymphoma.
- Your disease is relapsed or refractory, meaning it has either failed at least 2 prior treatment lines (including anti-CD20 medicines) or you had certain types of resistance or transplant-related recurrence.
- You have at least one measurable tumor spot (lymph node size or another tumor size that meets the study’s minimum measurements).
- You are generally able to do daily activities (ECOG 0 or 1) and can likely live at least 12 weeks.
- Your blood counts and organ tests (liver, kidneys, heart function, clotting, oxygen level) meet the study limits, and you can use effective birth control if you can become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This study tests a new therapy called CT1194C for people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. It aims to see if the therapy is safe and effective.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
Hear when a new B-cell Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.